Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06254495
Other study ID # SGN35C-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 31, 2024
Est. completion date August 31, 2028

Study information

Verified date April 2024
Source Seagen Inc.
Contact Seagen Trial Information Support
Phone 866-333-7436
Email clinicaltrials@seagen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.


Recruitment information / eligibility

Status Recruiting
Enrollment 170
Est. completion date August 31, 2028
Est. primary completion date February 28, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Tumor type - For dose escalation and dose optimization (Parts A and B): - Participants with a histologically confirmed lymphoid neoplasm who in the judgement of the investigator have no appropriate standard therapy available at the time of enrollment and are a candidate for SGN- 35C treatment. Eligible subtypes and treatment status are as follows: - Participants with relapsed/refractory (R/R) cHL: should have received at least 3 prior systemic therapies including autologous stem cell transplant [ASCT] (ASCT and the associated high-dose chemotherapy prior to ASCT are considered to be 1 prior line) or an anti-PD-1 agent (or refused/were ineligible); or 2 prior systemic therapies if, according to the investigator, no other appropriate standard treatment is available. - Participants with R/R PTCL (excluding systematic anaplastic large cell lymphoma [sALCL]): should have received at least 2 prior systemic therapies, or 1 prior systemic therapy if, according to the investigator, no other appropriate standard treatment is available. - Participants with R/R sALCL: should have received at least 2 prior systemic therapies, including 1 brentuximab vedotin-containing regimen, or 1 prior line of systemic therapy including brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone. - Participants with R/R DLBCL: should have received at least 2 prior systemic therapies, including ASCT and chimeric antigen receptor (CAR) T-cell therapy, or were ineligible, or refused. - Participants with PTCL and DLBCL must have a detectable cluster of differentiation 30 (CD30) expression level (=1%) in tumor tissue from the most recent biopsy obtained at or after relapse by local testing. - For dose expansion (Part C): - Participants are eligible irrespective of CD30 expression on tumor tissue; however, participants must provide tumor tissue for evaluation of CD30 expression from the most recent biopsy obtained at or after relapse. - Participants with cHL, PTCL, sALCL, and DLBCL: Eligible subtypes are the same as defined in Parts A and B - If activated, the biology cohort may enroll the populations included in Parts A, B, and C. - Eastern Cooperative Oncology Group (ECOG) Performance Status score of =1 - Fluorodeoxyglucose positron emission tomography (FDG-PET) avid and bidimensional measurable disease as documented by radiographic technique (spiral computed tomography [CT] preferred) Exclusion Criteria: - Previous exposure to any antibody-drug conjugates (ADCs) with camptothecin-based payload. - History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death - Active cerebral/meningeal disease related to the underlying malignancy - Received previous ASCT infusion <12 weeks prior to the first dose of SGN-35C. - Previous allogeneic stem cell transplant (SCT) if they meet any of the following criteria: - <100 days from allogeneic SCT. Participants =100 days from allogeneic SCT who are stable without immunosuppressive therapy for at least 12 weeks are permitted. - Active acute or chronic graft-versus-host disease (GVHD) or receiving immunosuppressive therapy as treatment for or prophylaxis against GVHD. - History of clinically significant GI bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of trial treatment.

Study Design


Intervention

Drug:
SGN-35C
Given into the vein (IV; intravenously)

Locations

Country Name City State
United States City of Hope Duarte California

Sponsors (1)

Lead Sponsor Collaborator
Seagen Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events (AEs) An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention , whether or not considered related to the study intervention Through 30-37 days after last study treatment, approximately 1 year
Primary Number of participants with laboratory abnormalities Through 30-37 days after last study treatment, approximately 1 year
Primary Number of participants with dose modifications due to AEs Up to approximately 1 year
Primary Number of participants with dose-limiting toxicities (DLTs) Up to 21 days
Primary Number of participants with DLTs by dose level Up to 21 days
Secondary Number of participants with antidrug antibodies (ADA) To be summarized using descriptive statistics Through 30-37 days after last study treatment, approximately 1 year
Secondary Area under the concentration time curve (AUC) To be summarized using descriptive statistics Through 30-37 days after last study treatment, approximately 1 year
Secondary Maximum concentration (Cmax) To be summarized using descriptive statistics Through 30-37 days after last study treatment, approximately 1 year
Secondary Time at which the maximum concentration occurs (Tmax) To be summarized using descriptive statistics Through 30-37 days after last study treatment, approximately 1 year
Secondary Apparent terminal half-life (t1/2) To be summarized using descriptive statistics Through 30-37 days after last study treatment, approximately 1 year
Secondary Trough concentration (Ctrough) To be summarized using descriptive statistics Through 30-37 days after last study treatment, approximately 1 year
Secondary Objective response rate (ORR) as assessed by the investigator A participant is determined to have an objective response if, based on Lugano criteria (Cheson 2014), they achieve a complete response (CR) or partial response (PR) as assessed by the investigator. The ORR is defined as the percentage of participants with an objective response. Up to approximately 1 year
Secondary CR rate as assessed by the investigator CR rate is defined as the proportion of participants with CR. Up to approximately 1 year
Secondary Duration of response (DOR) DOR is defined as the time from the start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per Lugano criteria (Cheson 2014) as assessed by the investigator or to death due to any cause, whichever comes first. Up to approximately 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT03977623 - Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
Recruiting NCT02428751 - R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma Phase 3
Completed NCT02555267 - Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
Active, not recruiting NCT02364050 - Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Terminated NCT02413489 - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma Phase 2
Completed NCT02086604 - Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Phase 1
Completed NCT01421524 - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Phase 1
Recruiting NCT03600363 - A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients Phase 2
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Recruiting NCT04446962 - LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) Phase 1/Phase 2
Withdrawn NCT03241017 - Durvalumab in DLBCL After Autologous Transplant Phase 2
Recruiting NCT02928861 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma N/A
Recruiting NCT02931201 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma N/A
Terminated NCT02592876 - Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma Phase 2
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Completed NCT00822432 - Coproporphyrine Isomers and Methotrexate Elimination N/A
Completed NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Phase 1
Recruiting NCT04982471 - Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Completed NCT03744676 - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Phase 2